516 related articles for article (PubMed ID: 33651840)
21. Association between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and community-acquired pneumonia: A nationwide population propensity-score matching study.
Lin SY; Chang SS; Lin CL; Lin CC; Hsu WH; Chou CH; Chi CY; Lin CD; Tu CY; Hsu CY; Kao CH
Int J Clin Pract; 2021 Oct; 75(10):e14476. PubMed ID: 34107133
[TBL] [Abstract][Full Text] [Related]
22. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
23. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
24. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
25. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study.
Lee HF; See LC; Chan YH; Yeh YH; Wu LS; Liu JR; Tu HT; Wang CL; Kuo CT; Chang SH
Intern Med J; 2018 Sep; 48(9):1123-1132. PubMed ID: 29808610
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
27. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
[TBL] [Abstract][Full Text] [Related]
28. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
[TBL] [Abstract][Full Text] [Related]
29. Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of COVID-19-Confirmed Cases and Deaths.
Tereshchenko LG; Johnson K; Khayyat-Kholghi M; Johnson B
Am J Cardiol; 2022 Feb; 165():101-108. PubMed ID: 34906367
[TBL] [Abstract][Full Text] [Related]
30. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
[TBL] [Abstract][Full Text] [Related]
32. A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes.
Mohan A; Majd Z; Johnson ML; Essien EJ; Barner J; Serna O; Gallardo E; Fleming ML; Ordonez N; Holstad MM; Abughosh SM
Drugs Aging; 2023 Apr; 40(4):377-390. PubMed ID: 36847995
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
Bean DM; Kraljevic Z; Searle T; Bendayan R; Kevin O; Pickles A; Folarin A; Roguski L; Noor K; Shek A; Zakeri R; Shah AM; Teo JTH; Dobson RJB
Eur J Heart Fail; 2020 Jun; 22(6):967-974. PubMed ID: 32485082
[TBL] [Abstract][Full Text] [Related]
34. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis.
Wu CK; Yang YH; Juang JJ; Wang YC; Tsai CT; Lai LP; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Medicine (Baltimore); 2015 Jan; 94(3):e424. PubMed ID: 25621694
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
36. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Grover A; Oberoi M
Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
[TBL] [Abstract][Full Text] [Related]
39. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
[TBL] [Abstract][Full Text] [Related]
40. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]